{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:37:12Z","timestamp":1787697432860,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>C\u2010reactive protein (CRP), the prototype human acute\u2010phase protein, is a well\u2010known marker of inflammation. However, CRP may also mediate tissue damage in various human diseases like atherosclerosis, acute myocardial infarction, dilated cardiomyopathy, stroke, and potentially autoimmune disease. Therefore, CRP elimination from human plasma may indeed be a widely usable therapeutic approach. Recently, a first\u2010in\u2010man case report of selective CRP\u2010apheresis in a patient with acute ST\u2010segment elevation myocardial infarction (STEMI) has been published. Here, the method is further elucidated by detailed description of 13 patients receiving CRP\u2010apheresis at two study centers. Thirteen patients received two sequential CRP\u2010apheresis treatments with the PentraSorb CRP adsorber starting 24\u2009\u00b1\u200912\u2009h after STEMI and successful percutaneous coronary intervention (PCI). CRP was measured immediately before and after each treatment, and additionally twice a day for a period of 96\u2009h after symptom onset. Compared to the initial (before\u2010treatment) CRP plasma concentration, CRP\u2010apheresis resulted in an average 53.4%\u2009\u00b1\u200911.9% CRP depletion. First apheresis was performed 27.5\u2009\u00b1\u20094.6\u2009h after symptom onset at a mean CRP concentration of 25.1\u2009\u00b1\u200911.1\u2009mg\/L. Mean CRP concentration after the first treatment was 12.1\u2009\u00b1\u20096.4\u2009mg\/L. Second apheresis started 47.9\u2009\u00b1\u20095.4\u2009h after symptom onset at a mean CRP concentration of 30.2\u2009\u00b1\u200921.4\u2009mg\/L. After the second treatment, mean CRP concentration was reduced to 13.9\u2009\u00b1\u200910.9\u2009mg\/L. No severe apheresis\u2010associated side effects were observed. Patients tolerated selective CRP\u2010apheresis without any side effects. The new method is feasible and safe and significantly reduces CRP plasma concentration in humans.<\/jats:p>","DOI":"10.1111\/1744-9987.12804","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T08:13:48Z","timestamp":1553847228000},"page":"570-574","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Selective C\u2010Reactive Protein\u2010Apheresis in Patients"],"prefix":"10.1111","volume":"23","author":[{"given":"Wolfgang","family":"Ries","sequence":"first","affiliation":[{"name":"Diakonissenhospital Flensburg Medical Clinic  Flensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Heigl","sequence":"additional","affiliation":[{"name":"Medical Care Center Kempten\u2010Allg\u00e4u  Kempten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Garlichs","sequence":"additional","affiliation":[{"name":"Diakonissenhospital Flensburg Medical Clinic  Flensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sheriff","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Infectiology and Rheumatology\u2014Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Torzewski","sequence":"additional","affiliation":[{"name":"Cardiovascular Center Oberallg\u00e4u\u2010Kempten  Kempten Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy633"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32814-3"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.9.1386"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.1.97"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-009-0026-2"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2013.06.015"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.4.3.379"},{"key":"e_1_2_5_10_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.113.1.9","article-title":"Interaction of C\u2010reactive protein complexes with the complement system. II. Consumption of Guinea pig complement by CRP complexes: requirement for human C1q","volume":"113","author":"Volanakis JE","year":"1974","journal-title":"J Immunol"},{"key":"e_1_2_5_11_1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.119.5.1611","article-title":"Mediation of CRP\u2010dependent phagocytosis through mouse macrophage fc\u2010receptors","volume":"119","author":"Mortensen RF","year":"1977","journal-title":"J Immunol"},{"key":"e_1_2_5_12_1","first-page":"4767105","article-title":"\"First in man\": case report of selective C\u2010reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction","volume":"2018","author":"Ries W","year":"2018","journal-title":"Case Rep Cardiol"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12796"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21344"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.47.833"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2017.69327"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.12804","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:37:46Z","timestamp":1694194666000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/1744-9987.12804"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12804","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"2019-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}